Pfizer released this Monday (22) new information regarding a study developed by the pharmaceutical in adolescents aged 12 to 15 years to determine the efficacy and safety of the immunization against covid-19 in the long term in this target audience , being identified that the vaccine maintains a satisfactory immune response and adequate levels of safety in this age group.
According to the statement, the third phase of the clinical study conducted in these individuals followed the guidelines stipulated by the FDA, a US health surveillance agency similar to Anvisa, and was carried out between November 2020 and September 2021, with the participation of 2,228 people in that period.
According to the data, all confirmed symptomatic patients with Sars-CoV-2 infection were in the group that received placebo — a drug that has no therapeutic effects — and none of the cases were reported among participants who received both doses of the vaccine. Pfizer/BioNTech, indicating 100% effectiveness.
The statement states that the effectiveness of the immunizer was “consistently high in demographics of gender, race and ethnicity, obesity and comorbidity status” and reiterates that the data from the 3rd phase of the study will be submitted for scientific peer review for potential publication.
These are the first and only released long-term data to demonstrate the safety and efficacy of a COVID-19 vaccine in individuals 12 to 15 years of age. […] The growing body of data we’ve compiled from clinical trials and real-world surveillance to date strengthens the evidence base that supports the strong efficacy and favorable safety profile of our COVID-19 vaccine in adolescent and adult populations. ”
Ugur Sahin,
CEO and co-founder of BioNTech.
How is the vaccination in your city? Have you ever been immunized? Tell us, comment!
